Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Virpax Pharmaceuticals Inc
(NQ:
VRPX
)
1.510
-0.160 (-9.58%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Virpax Pharmaceuticals Inc
< Previous
1
2
3
Next >
Virpax Pharmaceuticals to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET
June 13, 2023
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
Virpax Pharmaceuticals Reports 2023 First Quarter Results and Recent Developments
May 12, 2023
From
Virpax® Pharmaceuticals, Inc.
Via
Business Wire
Virpax Pharmaceuticals To Present at Upcoming CB Tech Watch Seminar
May 10, 2023
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference May 10-11, 2023
May 04, 2023
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
Virpax Pharmaceuticals Engages Dr. Pardeep Gupta to Assist in Development of Company’s Lead Asset, Probudur™
April 27, 2023
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
Virpax Reports on Progress of Envelta™
April 05, 2023
From
Virpax Pharmaceuticals
Via
Business Wire
Virpax Pharmaceuticals Announces Appointment of Barbara A. Ruskin, Ph.D, J.D. to the Board of Directors
March 28, 2023
From
Virpax Pharmaceuticals
Via
Business Wire
Virpax Pharmaceuticals Reports 2022 Year-End Results
March 22, 2023
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
Virpax Announces Positive Preclinical Toxicology Results in Support of Molecular Envelope Technology (MET)
February 13, 2023
From
Virpax Pharmaceuticals
Via
Business Wire
Virpax Pharmaceuticals Engages New England Investors to Direct Licensing Strategy for Envelta™ in China
January 31, 2023
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
Virpax Pharmaceuticals to Utilize Dr. Neil K. Singla to Assist in Development of Probudur™
January 18, 2023
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
Virpax Pharmaceuticals Engages Destum Partners to Direct Strategic Global Partnering Efforts
January 10, 2023
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
Virpax Pharmaceuticals Engages Dr. Kenneth W. Sommerville and Dr. Lawrence Fried to Assist in Development of NobrXiol™ (formerly VRP324)
January 04, 2023
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
Virpax Pharmaceuticals Reports on FDA Pre-IND Response for NobrXiol™ (formerly VRP324)
December 14, 2022
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
Virpax Pharmaceuticals Reports 2022 Third Quarter Results
November 09, 2022
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
Dr. Jeffrey Gudin, Chief Medical Officer of Virpax Pharmaceuticals, to Present Poster at World Congress of World Institute of Pain
August 24, 2022
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
Virpax Pharmaceuticals Reports 2022 Second Quarter Results and Recent Developments
August 15, 2022
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
Virpax Pursues OTC Medical Device Pathway for AnQlar™
July 05, 2022
From
Virpax Pharmaceuticals
Via
Business Wire
Virpax Will Pursue Direct to OTC Pathway for Epoladerm™ for Pain Associated with Osteoarthritis
June 27, 2022
From
Virpax Pharmaceuticals
Via
Business Wire
Virpax Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
May 19, 2022
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
Virpax Pharmaceuticals Reports 2022 First Quarter Results and Recent Developments
May 16, 2022
From
Virpax® Pharmaceuticals, Inc.
Via
Business Wire
Virpax Pharmaceuticals Enters Into CRADA With The U.S. Army Institute of Surgical Research
May 05, 2022
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
Virpax Successfully Completes Initial Preclinical Studies for VRP324
April 26, 2022
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
Virpax Pharmaceuticals Reports 2021 Year-End Results
March 31, 2022
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
Virpax Completes All FDA-Required Pre-Clinical Studies for Epoladerm™
March 22, 2022
From
Virpax® Pharmaceuticals, Inc.
Via
Business Wire
Nanomerics Receives Further Upfront Payment for Anti-Viral Spray AnQlar(TM)
March 22, 2022
LONDON, UK / ACCESSWIRE / March 22, 2022 / Nanomerics Ltd., a private speciality pharmaceutical company, today announced the receipt of a further milestone payment on agreeing the expansion of its...
From
Nanomerics Ltd
Via
AccessWire
Virpax Pharmaceuticals Expands AnQlar™ Development and Commercialization Rights Through Worldwide Licensing Agreement
March 15, 2022
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
News Outlets Highlight Virpax Pharmaceuticals and Its Potential Solutions for the Opioid Crisis and COVID-19
February 15, 2022
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
Virpax Reports Favorable Preclinical Safety Data for Envelta™ for the Treatment of Acute and Chronic Pain
February 10, 2022
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
Altasciences Chosen by Virpax Pharmaceuticals, Inc. to Conduct First-in-Human Study of Epoladerm™ for Chronic Pain Associated with Osteoarthritis of the Knee
January 21, 2022
From
Altasciences and Virpax Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.